NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Evaluating the Pharmacokinetics, Feasibility, Acceptability, and Safety of Oral Pre-Exposure Prophylaxis for HIV Prevention During Pregnancy and Postpartum

Phase 2

Completed

Conditions: HIV Infections

Interventions: Drug: Emtricitabine/Tenofovir Disoproxil Fumarate (FTC/TDF)
Behavioral: Behavioral HIV risk reduction package

First Posted Date: 2017-12-29

Last Posted Date: 2024-07-16

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 390

Registration Number: NCT03386578

Locations: 🇺🇬
MU-JHU Care Limited CRS, Kampala, Uganda
🇺🇬
Baylor-Uganda CRS, Kampala, Uganda
🇲🇼
Blantyre CRS, Blantyre, Malawi

and more 4 locations

Evaluating the Safety and Serum Concentrations of a Human Monoclonal Antibody, VRC-HIVMAB075-00-AB (VRC07-523LS), Administered in Multiple Doses and Routes to Healthy, HIV-uninfected Adults

Phase 1

Completed

Conditions: HIV Infections

Interventions: Biological: VRC07-523LS
Biological: Placebo

First Posted Date: 2017-12-29

Last Posted Date: 2023-04-05

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 124

Registration Number: NCT03387150

Locations: 🇨🇭
Lausanne Vaccine and Immunotherapy Center CRS, Lausanne, Vaud, Switzerland
🇺🇸
The Ponce de Leon Center CRS, Atlanta, Georgia, United States
🇺🇸
Alabama CRS, Birmingham, Alabama, United States

and more 4 locations

Evaluating the Infectivity, Safety, and Immunogenicity of a Respiratory Syncytial Virus Vaccine (RSV 6120/∆NS2/1030s) in RSV-Seropositive Children and RSV-Seronegative Infants and Children

Phase 1

Completed

Conditions: RSV Infection

Interventions: Biological: RSV 6120/∆NS2/1030s
Biological: Placebo

First Posted Date: 2017-12-29

Last Posted Date: 2024-12-11

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 45

Registration Number: NCT03387137

Locations: 🇺🇸
Center for Immunization Research, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, United States

Selective Estrogen Receptor Modulators to Enhance the Efficacy of Viral Reactivation With Histone Deacetylase Inhibitors

Phase 2

Completed

Conditions: HIV Infections

Interventions: Drug: Tamoxifen
Drug: Vorinostat
Drug: Antiretroviral drugs

First Posted Date: 2017-12-26

Last Posted Date: 2024-07-03

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 31

Registration Number: NCT03382834

Locations: 🇺🇸
Penn Therapeutics, CRS, Philadelphia, Pennsylvania, United States
🇺🇸
Massachusetts General Hospital CRS (MGH CRS), Boston, Massachusetts, United States
🇺🇸
Cincinnati Clinical Research Site, Cincinnati, Ohio, United States

and more 12 locations

Evaluating the Safety and Immunogenicity of an HIV Vaccine (gp145 C.6980) in Healthy, HIV-Uninfected Adults in the United States

Phase 1

Completed

Conditions: HIV Infections

Interventions: Biological: gp145 C.6980 Vaccine
Biological: Placebo
Biological: Aluminum Hydroxide Adjuvant

First Posted Date: 2017-12-22

Last Posted Date: 2021-10-08

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 45

Registration Number: NCT03382418

Locations: 🇺🇸
New York Blood Center CRS, New York, New York, United States
🇺🇸
Columbia P&S CRS, New York, New York, United States
🇺🇸
Penn Prevention CRS, Philadelphia, Pennsylvania, United States

Safety and Tolerability of AAV8 Delivery of a Broadly Neutralizing Antibody in Adults Living With HIV: a Phase 1, Dose-escalation Trial

Phase 1

Active, not recruiting

Conditions: HIV-1 Infected Adults With Controlled Viremia

Interventions: Genetic: VRC-HIVAAV070-00-GT (AAV8-VRC07)

First Posted Date: 2017-12-15

Last Posted Date: 2023-10-25

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 10

Registration Number: NCT03374202

Locations: 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States

Minocycline Pharmacokinetics (ACUMIN)

Phase 4

Completed

Conditions: Bacterial Infection

Interventions: Drug: Minocycline

First Posted Date: 2017-12-12

Last Posted Date: 2020-12-03

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 58

Registration Number: NCT03369951

Locations: 🇺🇸
Northwestern Memorial Hospital - ICU, Chicago, Illinois, United States
🇺🇸
University of Louisville School of Medicine - Surgery, Louisville, Kentucky, United States
🇺🇸
Washington University School of Medicine in St. Louis - Infectious Diseases, Saint Louis, Missouri, United States

and more 12 locations

Ustekinumab (Anti-IL-12/23p40 Monoclonal Antibody) in Patients With Leukocyte Adhesion Deficiency Type 1 (LAD1) Who Have Inflammatory Pathology

Phase 1

Completed

Conditions: LAD1

Interventions: Drug: Ustekinumab

First Posted Date: 2017-12-08

Last Posted Date: 2024-10-22

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 6

Registration Number: NCT03366142

Locations: 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States

Placebo-Controlled Trial of Antibiotic Therapy in Adults With Suspect Lower Respiratory Tract Infection (LRTI) and a Procalcitonin Level

Not Applicable

Terminated

Conditions: Lower Respiratory Tract Infection

Interventions: Drug: Azithromycin
Other: Placebo
Device: VIDAS B.R.A.H.M.S Procalcitonin Test (PCT)

First Posted Date: 2017-11-14

Last Posted Date: 2023-06-28

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 514

Registration Number: NCT03341273

Locations: 🇺🇸
The Hope Clinic of Emory University, Atlanta, Georgia, United States
🇺🇸
Atlanta VA Medical Center - Infectious Diseases Clinic, Decatur, Georgia, United States
🇺🇸
Texas Medical Center - Michael E. DeBakey Veterans Affairs, Houston, Texas, United States

and more 2 locations

Evaluating the Pharmacokinetics, Safety, and Tolerability of Doravirine (MK-1439) and Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate (MK-1439A) in HIV-1-Infected Children and Adolescents

Phase 1

Completed

Conditions: HIV Infections

Interventions: Drug: Doravirine (DOR)
Drug: Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate (DOR/3TC/TDF)
Drug: Antiretroviral (ARV) medications

First Posted Date: 2017-11-06

Last Posted Date: 2023-02-14

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 55

Registration Number: NCT03332095

Locations: 🇹🇭
Siriraj Hospital ,Mahidol University NICHD CRS, Bangkok, Bangkoknoi, Thailand
🇹🇭
Chiang Mai University HIV Treatment (CMU HIV Treatment) CRS, Chiang Mai, Thailand
🇺🇸
Univ. of Colorado Denver NICHD CRS, Aurora, Colorado, United States

and more 5 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy